Inscripta® Announces Strategic Acquisition of Solana Biosciences
Adds former Illumina operations team to develop and commercialize gene-editing technology
Read More
Inscripta® Granted Patents for CRISPR Gene-Editing Systems
New data shows Inscripta’s MADzymes edit in mammalian cells
Read More
Inscripta® Raises $55.5 Million to Advance Gene-Editing Technology
Investment will grow company’s expert team, accelerate development and commercialization of gene-editing tools — including enzymes, reagents, instrumentation, and software
Read More
Inscripta® Adds World-Renowned Protein-Engineering AI Expert to Executive Team
Gene-editing technology company accelerates machine learning approaches to forward engineer living systems
Read More
Inscripta® Releases New, Unique CRISPR Gene-Editing Enzyme; Free to Use for All Researchers
First Product Release from Inscripta’s Enzyme Engineering Platform
Read More
Muse bio appoints genomics industry expert, John Stuelpnagel, as Chairman of the Board of Directors
Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first...
Read More
Muse bio secures $23M Series B financing led by Venrock
Genome engineering company assembles world-class investor syndicate to advance development of its gene editing and single-cell writing technology
Read More
Nature Biotechnology paper details high-throughput, multiplexed CRISPR technology
Revolutionary technology licensed by Muse bio enables precise, genome-wide engineering
Read More